-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since the discovery of Ivermectin by the Kitasato Research Institute in Tokyo, Ivermectin has been used to treat some of the most durable tropical diseases in the world.
Tapeworms, flukes and protozoa are invalid
.
However, due to its poor solubility, its ability to be converted into liquid has been declining.
Now, scientists at the Canadian pharmaceutical company Mountain Valley MD claim to have found a way to dissolve the drug into a substance they call Ivectosol
.
They say this opens up the possibility of using the drug in combination with existing checkpoint inhibitors to target cancer cells more effectively
.
Checkpoint inhibitors are a class of drugs that help the human immune system detect and eradicate cancer cells
.
Although the results are still in the preliminary stages, Mountain Valley believes that their new drug Ivectosol may be a "true game changer" in cancer treatment
"Imagine what might happen when you have the world's only form of human injection that can be injected directly into a tumor or intravenously
.
We believe these routes of administration will be suitable for a variety of aggressive cancers
For example, in triple-negative breast cancer, only 20% of tumors are recognized by the best checkpoint inhibitors today
The company has conducted three independent preclinical trials to continue to study its use as a cancer treatment
The trials aim to make the drug fight some of the most difficult cancers in the world, including triple-negative breast cancer, metastatic melanoma and non-small cell lung cancer
Since Ivermectin has been widely understood, Mountain Valley MD hopes that they can bring new products to the market faster than other methods
In the United States, they have applied to the FDA (U.
If approved, this may mean that ivermectin will be ready for human application in the United States by early 2022
And because the US market is considered the benchmark for most of the rest of the world, it will receive global approval shortly thereafter
Mountain Valley MD has applied for patent protection, and the patented solubility technology powers the drug
